Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans

Circulation

Volumn 94, Issue 7, 1996, Pages 1592-1599

  Démolis, Jean Louis ^d   Funck Brentano, Christian ^d   Ropers, Jacques ^d   Ghadanfar, Mathieu ^a   Nichols, Donald J ^b   Jaillon, Patrice ^c  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c HÔPITAL SAINT ANTOINE   (France)

^d NONE

Author keywords

antiarrhythmia agents; drugs; potassium

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISPERSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EXERCISE TEST; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; R WAVE; RANDOMIZED CONTROLLED TRIAL;

EID: 0029741236     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.7.1592     Document Type: Article

References (43)

1. Gwilt M, Arrowsmith JE, Blackburn KJ, Burges RA, Cross PE, Dalrymple HW, Higgins AJ. UK 68,798 is a novel, potent, and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther. 1991;256:318-324.
2. Vaughan Williams EM. A classification of antiarrhythmic drugs reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24:129-147.
3. Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol. 1989;63:867-869.
4. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Cœur Vaiss. 1966;59:263-272.
5. Stratmann HG, Kennedy HL. Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J. 1987; 113:1470-1482.
6. Benedict CR. The QT interval and drug-associated torsades de pointes. Drug Invest. 1993;5:69-79.
7. Day CP, McComb JM, Campbell RWF. QT dispersion: an indication of antiarrhythmic risk in patients with long QT intervals. Br Heart J. 1990;63:342-344.
8. Statters DJ, Malik M, Ward DE, Camm AJ. QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol. 1994;5:672-685.
9. Hii JTY, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsades de pointes: disparate effects of class la antiarrhythmic drugs and amiodarone. Circulation. 1992;86:1376-1382.
10. Zareba W, Moss AJ, le Cessie S. Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease. Am J Cardiol. 1994;74:550-553.
11. Roden DM, Woosley RL. QT prolongation and arrhythmia suppression. Am Heart J. 1985;109:411-415.
12. McKibbin JK, Pocock WA, Barlow JB, Millar RNS, Obel IWP. Sotalol, hypokalemia, syncope and torsades de pointes. Br Heart J. 1984;51:157-162.
13. Gwilt M, Blackburn KJ, Surges RA, Higgins AJ, Solca AM, Milne AA. Electropharmacology of dofetilide, a new class III agent, in anaesthetized dogs. Eur J Pharmacol. 1992;215:137-144.
14. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation. 1990;81:686-690.
15. Funck-Brentano C, Coudray P, Planellas J, Motté G, Jaillon P. Effects of bepridil and diltiazem on ventricular repolarization in angina pectoris. Am J Cardiol. 1990;66:812-817.
16. Funck-Brentano C, Kibleur Y, Le Coz F, Poirier JM, Mallet A, Jaillon P. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans. Circulation. 1991;83:536-545.
17. Funck-Brentano C. Rate dependence of class III actions in the heart. Fundam Clin Pharmacol. 1993;7:51-59.
18. Cobbe SM, Alexopoulos D, Winner SJ, McCaie CP, Cobbe PC, Johnstone J. A comparison of the long term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction. Eur Heart J. 1988;9:24-31.
19. K blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol. 1990;16:401-410.
20. Day CP, McComb JM, Matthews J, Campbell RWF. Reduction in QT dispersion by sotalol following myocardial infarction. Eur Heart J. 1991;12:423-427.
21. Schmitt C, Brachmann J, Karch M, Waldecker B, Navarrete L, Montera M, Beyer T, Kübler W. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle. Am J Cardiol. 1991;68:1183-1187.
22. Gemmil JD, Howie CA, Meredith PA, Kelman AW, Rasmussen HS, Hillis WS, Elliot HL. A dose-ranging study of UK-68,798, a novel class III antiarrhythmic agent, in normal volunteers. Br J Clin Pharmacol. 1991;32:429-432.
23. max. Br J Pharmacol. 1991;103:1568-1572.
24. Sedgwick M, Rasmussen HS, Walker D, Cobbe SM. Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug. Br J Clin Pharmacol. 1991;31:515-519.
25. Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol. 1992;70:1432-1437.
26. Hohnloser SH, van de Loo A, Kalusche D, Arendts W, Quart B. Does sotalol-induced alteration of QT-dispersion predict drug effectiveness or proarrhythmic hazards? Circulation. 1993;88(pt 2):397. Abstract.
27. + current by dofetilide. Circ Res. 1993;72:75-83.
28. Todt H, Zojer N, Schütz W. Differential effect of dofetilide on ventricular repolarization during steady state and during restitution in vivo. J Cardiovasc Pharmacol. 1994;24:1010-1013.
29. Yuan S, Wohlfart B, Rasmussen HS, Olsson S, Blomström-Lundqvist C. Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia. Eur Heart J. 1994;15:514-522.
30. Kr blockers dofetilide, D-Sotalol, E-4031, and MK-499. J Cardiovasc Pharmacol. 1994;24:199-206.
31. Le Coz F, Funck-Brentano C, Morell T, Ghadanfar MM, Jaillon P. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin Pharmacol Ther. 1995;57:533-542.
32. Fananapazir L, Cropp A. Dofetilide (UK 68,798) prevents ventricular tachycardia on Holter and inducible sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;19(suppl A):224A. Abstract.
33. Brachmann J, Haverkamp W, Johns J, Zehender M, Kingma HG, Wiecha J. The efficacy and safety of oral dofetilide in patients with sustained ventricular tachycardia. Circulation. 1992;86(suppl I):I-265. Abstract.
34. Rasmussen HS, Allen MJ, Butrous GS, Dalrymple HW. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol. 1992;20(suppl 2):S96-S105.
35. Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation. 1952;6:378-388.
36. Hnatkova K, Malik M, Kautzner J, Gang V, Camm AJ. Adjustment of QT dispersion assessed from 12-lead electrocardiograms for different numbers of analysed electrocardiographic leads: comparison of stability of different methods. Br Heart J. 1994;72:390-396.
37. Walker DK, Herne G, Arrowsmith JE, Cross PE, Kaye MB, Smith DA, Stopher DA, Wild W. Measurement of the class III antiarrhythmic agent UK-68,798 in plasma by radioimmunoassay. J Pharm Biomed Anal. 1991;9:141-149.
38. Sarma JSM, Sarma JR, Bilitch M, Katz D, Song SL. An exponential formula for heart dependence of QT interval during exercise and cardiac pacing in humans: reevaluation of Bazett's formula. Am J Cardiol. 1984;54:103-108.
39. Lecocq B, Lecocq V, Jaillon P. Physiologic relation between cardiac cycle and QT duration in healthy volunteers. Am J Cardiol. 1989;63:481-486.
40. Williams ME, Gervino EV, Rosa DM, Landsberg L, Young JB, Silva P, Epstein FH. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med. 1985;312:823-827.
41. Kr: implications for torsade de pointes and reverse use-dependence. Circulation. 1996;93:407-411.
42. + current in cardiac myocytes with dofetilide. J Pharmacol Exp Ther. 1992;262:809-817.
43. Funck-Brentano C, Jaillon P. Rate-corrected QT interval duration: techniques and limitations. Am J Cardiol. 1993;72:1B-7B.